AN ANALYSIS COMPARING THE EFFICACY OF NARLAPREVIR WHEN COMBINED WITH INTERFERON AND INTERFERON-FREE THERAPY REGIMENS FOR INDIVIDUALS SUFFERING FROM CHRONIC HEPATITIS C

This article presents a comparative analysis of the efficacy of narlaprevir in conjunction with two different treatment regimens, namely interferon-based therapy and interferon-free therapy, in individuals with chronic hepatitis C. The authors investigate various clinical parameters such as virological response rates, treatment duration, adverse effects, and sustained virologic response (SVR) rates to assess the effectiveness of narlaprevir within each treatment protocol. By examining both traditional interferon-based therapy and newer interferon-free regimens, the study offers insights into the evolving landscape of hepatitis C treatment options. The findings contribute to the understanding of optimal treatment strategies for chronic hepatitis C patients, with implications for clinical decision-making and healthcare policy development. This analysis aims to inform healthcare practitioners and policymakers about the relative efficacy and safety profiles of narlaprevir in different treatment contexts, ultimately aiming to improve patient outcomes in the management of chronic hepatitis C.